LifeVantage (LFVN) AI Stock Analysis

• Market Cap: $57.95M
• Dividend Yield: 2.81%
• Average Volume (3M): 270.88K
• Price to Earnings (P/E): 7.6
• Beta (1Y): -0.02
• Revenue Growth: 16.77%
• EPS Growth: 143.30%
• Country: US
• Employees: 222
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): -0.02
• Shares Outstanding: 12,793,359
• 10 Day Avg. Volume: 177,169
• 30 Day Avg. Volume: 270,877
• PEG Ratio: 0.07
• Price to Book (P/B): 4.63
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 15.25
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 0.29
• Enterprise Value/Gross Profit: 0.36
• Enterprise Value/Ebitda: 5.08
• 1Y Price Target: $5.00
• Price Target Upside: -26.04% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.78
• Revenue Forecast (FY): $204.89M

• Rating: 56 Neutral
• Price Target: $5.00 ▼(-26.04% Downside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is driven primarily by mixed fundamentals: strong margins and a solid balance sheet are offset by deteriorating cash flow and recent revenue contraction. Technicals add pressure due to a clear downtrend, while valuation (low P/E and dividend yield) provides meaningful support. Earnings call takeaways are mixed—supportive guidance and capital returns are outweighed by steep YoY revenue decline, margin pressure, weak cash generation, and leadership transition risk.

Positive Factors

LoveBiome Acquisition & Product Pipeline

The LoveBiome acquisition immediately added meaningful product revenue and early synergies, diversifying LifeVantage’s portfolio away from a single recent launch. Successful integration and staged product rollouts create a durable channel for incremental revenue and reduce concentration risk over the coming quarters.

Very High Gross Margins & Improving Profitability

Sustained gross margins near 80% indicate strong product economics and pricing power in core supplement/skincare lines. Improved net margins show operating leverage when volumes recover, providing long-term capacity to fund R&D, marketing, or shareholder returns even if top-line growth is uneven.

Clean Balance Sheet & Shareholder Returns

A low-leverage balance sheet combined with explicit buyback and dividend programs signal financial flexibility and disciplined capital allocation. With reported cash available and manageable debt metrics, management can support returns while investing in growth, a durable structural advantage in downturns.

Negative Factors

Sharp Revenue Decline & GLP-1 Exposure

A near-28% YoY revenue drop demonstrates material exposure to the GLP-1 product cycle and volatile end-market dynamics. Reliance on a recently launched weight-loss system created concentration risk, making top-line recovery contingent on regaining demand or successfully shifting sales to new product lines.

Weakened Cash Generation & FCF Volatility

Sharp deterioration in operating cash flow and an 80% drop in free cash flow constrain reinvestment and reduce buffer against shocks. Weak cash conversion versus earnings heightens liquidity risk and limits the company’s ability to sustainably fund marketing, new product launches, or absorb further inventory shocks.

Inventory Reserve & Distributor Base Decline

A one-time $2.4M inventory write allowance reflects product obsolescence risk in a fast-moving category. Concurrently, a steep drop in active accounts signals erosion of the distributor/customer base in its primary market, a structural headwind that pressures future sales and raises fixed-cost leverage in the MLM model.

LifeVantage Business Overview & Revenue Model

Company Description

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.

How the Company Makes Money

LifeVantage generates revenue primarily through direct sales of its products, utilizing a multi-level marketing (MLM) business model. Independent distributors sell LifeVantage products directly to consumers and earn commissions based on their sales and the sales made by their recruited team members. This creates a tiered compensation structure that incentivizes recruitment and sales. Key revenue streams include product sales, distributor fees, and commissions from the MLM structure. Additionally, the company may engage in partnerships with other health and wellness brands or distributors to expand its market reach and enhance its product offerings, further contributing to its earnings.

LifeVantage Financial Statement Overview

Summary

Profitability and balance sheet quality are strengths (very high gross margins, improved net/operating margins, moderate leverage and strong ROE), but the overall profile is held back by TTM revenue contraction and notably weaker cash generation/FCF (sharp FCF decline and low OCF-to-net-income conversion).

Income Statement

TTM (Trailing-Twelve-Months) revenue declined (-7.9%), following a stronger FY2025 (+14.2%) after a softer FY2024 (-6.2%), highlighting an uneven top-line trajectory. Profitability is a clear strength: gross margin remains exceptionally high (~80%+), and net margin improved materially versus FY2023–FY2024 (TTM ~4.8% vs ~1–1.5% previously), with EBIT/EBITDA margins also recovering into the mid-single digits. Overall, the income statement reflects a healthier profit profile, but recent revenue contraction keeps the score from the top tier.

Balance Sheet

Leverage looks manageable with debt-to-equity around ~0.34 in FY2025 and TTM, an improvement versus FY2024 (~0.52). Equity remains positive and the business is generating strong returns on equity (TTM ~38% and FY2025 ~28%), reflecting improved earnings power relative to the capital base. The main watch item is that total assets fell from FY2025 to TTM, but overall the balance sheet appears solid and not overly debt-dependent.

Cash Flow

Cash generation weakened meaningfully in TTM (Trailing-Twelve-Months): operating cash flow dropped to ~$3.7M and free cash flow to ~$1.7M, with free cash flow down sharply (-80.5%). While free cash flow remains close to net income (TTM ~0.86x), operating cash flow covers only about half of net income in TTM (~0.54x), indicating earnings are currently converting to cash less efficiently than in prior years (e.g., FY2025 operating cash flow was much stronger). This volatility and recent deterioration weigh on the score.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	210.05M	228.53M	200.16M	213.40M	206.36M	220.18M
Gross Profit	165.40M	183.67M	158.72M	170.01M	168.26M	181.99M
EBITDA	11.87M	15.36M	7.91M	7.84M	7.96M	21.07M
Net Income	7.86M	9.80M	2.94M	2.54M	3.12M	12.89M
Balance Sheet
Total Assets	61.17M	71.96M	60.30M	66.12M	70.71M	78.73M
Cash, Cash Equivalents and Short-Term Investments	10.18M	20.20M	16.89M	21.61M	20.19M	23.17M
Total Debt	10.69M	11.68M	13.61M	13.09M	15.76M	18.18M
Total Liabilities	28.18M	37.32M	34.31M	31.47M	39.19M	41.92M
Stockholders Equity	32.99M	34.64M	25.99M	34.65M	31.52M	36.81M
Cash Flow
Free Cash Flow	1.70M	10.51M	9.95M	3.76M	6.43M	6.43M
Operating Cash Flow	3.75M	11.88M	12.20M	6.83M	7.96M	7.96M
Investing Cash Flow	-5.80M	-1.37M	-2.25M	-3.06M	-1.53M	-1.53M
Financing Cash Flow	-9.40M	-7.60M	-14.42M	-2.36M	-8.95M	-8.95M

LifeVantage Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Negative. The current price of 6.76 is above the 20-day moving average (MA) of 5.13, above the 50-day MA of 5.78, and below the 200-day MA of 9.59, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 34.36 is Neutral, neither overbought nor oversold. The STOCH value of 16.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFVN.

LifeVantage Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	80 Outperform	$473.25M	33.94	9.52%	―	6.62%	-7.85%
HLF	63 Neutral	$2.03B	8.76	―	―	-0.78%	265.56%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LFVN	56 Neutral	$57.95M	7.57	25.00%	2.81%	16.77%	143.30%
USNA	56 Neutral	$395.96M	37.96	3.20%	―	5.88%	-68.62%
HAIN	46 Neutral	$70.57M	-0.13	-95.83%	―	-10.13%	-532.32%

LifeVantage Corporate Events

LifeVantage Reports Weaker Q2 Results, Launches Buyback Program

On January 30, 2026, LifeVantage announced that President and CEO Steven R. Fife plans to retire from his roles, including his board seat, with his resignation expected to take effect in April 2026, and the company emphasized that his decision was not related to any dispute over operations or financial policies. On February 4, 2026, the company reported that second-quarter fiscal 2026 revenue for the period ended December 31, 2025 fell 27.8% year on year to $48.9 million, with sharp declines in Americas sales and softer performance in Asia/Pacific and Europe, as the business cycled last year’s launch of the MindBody GLP-1 System™ and recorded lower profitability, including net income of $0.3 million, or $0.02 per diluted share, and adjusted EBITDA of $3.9 million. Management acknowledged competitive pressure in the weight-loss market and weaker-than-expected results, but pointed to growing momentum in the recently acquired LoveBiome® line, planned international expansion and new product launches as levers to restore growth, even as cash generation and cash balances declined over the first half of fiscal 2026 and gross margins were hit by inventory obsolescence tied to the GLP-1 product. Despite the earnings pressure, LifeVantage signaled confidence in its long-term strategy by unveiling a new $60 million share repurchase program to run through 2027, declaring a quarterly dividend of $0.045 per share payable March 16, 2026, and reiterating full-year fiscal 2026 guidance that foresees $185 million to $200 million in revenue and improved adjusted profitability, framing the current year as a transition period focused on portfolio diversification and shareholder returns.

The most recent analyst rating on (LFVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on LifeVantage stock, see the LFVN Stock Forecast page.

LifeVantage Announces Resignation of Two Key Executives

On December 3, 2025, LifeVantage Corporation announced the resignations of two key executives. Julie Boyster, the Chief Marketing Officer, will leave her position on December 12, 2025, and Todd Thompson, the Chief Information and Innovation Officer, will depart on December 24, 2025, both to pursue other business opportunities.

The most recent analyst rating on (LFVN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on LifeVantage stock, see the LFVN Stock Forecast page.

LifeVantage Holds Annual Stockholders Meeting, Elects Directors

LifeVantage Corporation held its fiscal year 2026 annual meeting of stockholders on November 6, 2025, where 75.41% of the company’s common stock was represented. During the meeting, stockholders elected seven directors to the board, approved executive compensation on an advisory basis, ratified Deloitte & Touche as the independent accounting firm, and approved an amendment to the 2017 Long-Term Incentive Plan.

The most recent analyst rating on (LFVN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on LifeVantage stock, see the LFVN Stock Forecast page.